

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitution for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 3, 2004 (use as many sheets as necessary)		Complete if Known	
Application Number		09/877,633	
Filing Date		06/08/2001	
Inventor(s):		Lal et al.	
Group Art Unit		1652	
Examiner Name		Slobodyansky, Elizabeth	
Attorney Docket Number		039386-0536	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
ES		BLAST results for SEQ ID NO:1, at National Center for Biotechnology Information database searching for short nearly exact amino acid sequences	
ES		GenBank Accession No. BAB62751, Submitted by Onouchi et al., <u>unpublished</u> (August 9, 2001)	
ES		Wakata, et al., Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study, INT. J. DERMATOL., 41:729-34 (2002)	
ES		Langan et al., Dermatomyositis associated with angiotropic lymphoma, CLIN. DERMATOL., 28:597-599 (2003)	
ES		Gluck et al., Dermatomyositis, carcinoma of colon and meningioma in the same patient, J. DERMATOL., 20:719-22 (1993)	
ES		Apaydin et al., J. EUR. ACAD. DERMATOL. VENEREOL., 16:172-4 (2002)	
ES		Hagman et al., Dermatomyositis associated with ovarian transitional carcinoma, J. AM. ACAD. DERMATOL., 45:642-4 (2001)	
ES		Di Stasi, et al., Dermatomyositis associated with testicular germ cell cancer, J. UROL., 163:240 (2000)	
ES		Zhang et al., The Dermatomyositis-Specific Autoantigen Mi2 Is a Component of a Complex Containing Histone Deacetylase and Nucleosome Remodeling Activities, Cell, 95:279-89 (1998)	

Examiner Signature	<i>E. Slobodyansky</i>	Date Considered	11/10/04
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: September 3, 2004

(Use as many sheets as necessary)

2

of

2

Complete if Known

Application Number	09/877,633
Filing Date	06/08/2001
Inventor(s):	Lal et al.
Group Art Unit	1652
Examiner Name	Slobodyansky, Elizabeth
Attorney Docket Number	039386-0536

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
ES		Targoff, <i>Idiopathic inflammatory myopathy: autoantibody update</i> , CURR. RHEUMATOL. REP., 4:434-41 (2002)	
ES		GenBank Accession No. NP_060268, Ota et al., Nat. Genet. 36 (1), 40-45 (2004)	
ES		Stoilov et al., <i>YTH: a new domain in nuclear proteins</i> , TRENDS IN BIOCHEM. SCI., Vol. 27, pp. 495-497 (2002)	
ES		Targoff et al., <i>Humoral immunity in polymyositis/dermatomyositis</i> , J. INVEST. DERMATOL., 100:116S-123S (1993)	

Examiner
Signature

E. Slobodyansky

Date
Considered

11/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.